CA3131741A1 - Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines - Google Patents

Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines Download PDF

Info

Publication number
CA3131741A1
CA3131741A1 CA3131741A CA3131741A CA3131741A1 CA 3131741 A1 CA3131741 A1 CA 3131741A1 CA 3131741 A CA3131741 A CA 3131741A CA 3131741 A CA3131741 A CA 3131741A CA 3131741 A1 CA3131741 A1 CA 3131741A1
Authority
CA
Canada
Prior art keywords
oligomer
conjugate
hexylspacer
immunogenic composition
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3131741A
Other languages
English (en)
French (fr)
Inventor
Roberto ADAMO
Francesco Berti
Paolo Costantino
Luigi LAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CA3131741A1 publication Critical patent/CA3131741A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3131741A 2019-03-08 2020-03-06 Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines Pending CA3131741A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19161716.6 2019-03-08
EP19161716 2019-03-08
PCT/EP2020/055950 WO2020182635A1 (en) 2019-03-08 2020-03-06 Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines

Publications (1)

Publication Number Publication Date
CA3131741A1 true CA3131741A1 (en) 2020-09-17

Family

ID=66000932

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3131741A Pending CA3131741A1 (en) 2019-03-08 2020-03-06 Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines

Country Status (8)

Country Link
US (1) US20220152183A1 (enExample)
EP (1) EP3934696A1 (enExample)
JP (2) JP7728704B2 (enExample)
CN (1) CN114126662A (enExample)
BR (1) BR112021017239A2 (enExample)
CA (1) CA3131741A1 (enExample)
MX (1) MX2021010555A (enExample)
WO (1) WO2020182635A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
JP4827726B2 (ja) 2003-01-30 2011-11-30 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 複数の髄膜炎菌血清群に対する注射可能ワクチン
GB0409750D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Integration of meningococcal conjugate vaccination
SI3110442T1 (sl) 2014-02-28 2021-01-29 Glaxosmithkline Biologicals S.A. Modificirani meningokokni fHbp polipeptidi
GB202013262D0 (en) * 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition

Also Published As

Publication number Publication date
CN114126662A (zh) 2022-03-01
JP2025111445A (ja) 2025-07-30
US20220152183A1 (en) 2022-05-19
JP2022523570A (ja) 2022-04-25
WO2020182635A1 (en) 2020-09-17
MX2021010555A (es) 2022-04-06
JP7728704B2 (ja) 2025-08-25
EP3934696A1 (en) 2022-01-12
BR112021017239A2 (pt) 2021-11-09

Similar Documents

Publication Publication Date Title
CA2961694C (en) Vaccines against streptococcus pneumoniae serotype 8
MX2007013881A (es) Inmunogenos para vacunas de meningitides-a.
US10087242B2 (en) Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X
JP2025111445A (ja) 炭素環誘導体及びそれらのコンジュゲート誘導体、並びにワクチンにおけるそれらの使用
EP3274358B1 (en) Vaccine against carbapenem-resistantklebsiella pneumoniae
JP6622804B2 (ja) ストレプトコッカス ニューモニアエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）血清型４に対するワクチン
CN106432371A (zh) β‑1,2‑D‑寡聚甘露糖蛋白缀合物及其制备方法和应用
US20230346905A1 (en) Pentavalent vaccine against neisseria meningitidis comprising a synthetic men a antigen
KR102803369B1 (ko) 클로스트리듐 디피실에 대한 안정성 백신
US10376593B2 (en) Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri
US20250161428A1 (en) Preventing/treating pseudomonas aeruginosa infection
Auberger Synthesis of Neisseria meningitidis serogroup A carba analogues as hydrolytically stable antigens for antimeningococcal glycoconjugate vaccines
Koutha Synthetic studies toward pseudopentasaccharide repeating unit of Streptococcus pneumoniae zwitterionic polysaccharide
HK1242329B (en) Vaccines against streptococcus pneumoniae serotype 8
HK1242329A1 (en) Vaccines against streptococcus pneumoniae serotype 8

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240219